Skip to main content

Advertisement

Table 3 Immunophenotype of 7 patients with AML-M2/M3 by FCM

From: Clinical and laboratory features of seven patients with acute myeloid leukemia (AML)-M2/M3 and elevated myeloblasts and abnormal promyelocytes

No. CD45(blast) CD9 CD13 CD33 CD34 cMPO CD117 HLA-DR CD11b CD15 CD38 CD56 D64
Case 1 81.1 47.5 32.7 46.9 41.0
Case 2 69.0 47.0 62.9 78.1 55.1 85.4
Case 3 80.3 93.2 87.2 97.3 16.2 96.4
Case 4 83.7 92.5 97.0 98.9 16.4 12.7 86.7
Case 5 76.4 30.9 95.5 78.4 78.4 11.6 96.5 16.9
Case 6 44.9 CD34/HLA-DR 29.6%, CD15 6.5%, CD14/CD11b 0.2%, HLA-DR/CD13 3.5%
Case 7 84.5 36.2 90.8 82.6 62.3 97.8 88.0 85.9 13.5 40.3 12.4 7.9
48.3 94.9 83.0 98.9 43.8 35.0 46.6 95.3 26.1 70.4
  1. ―, these antibodies were expressed in less than 10% of cells.